X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.
Lead Product(s): Resveratrol
Therapeutic Area: Genetic Disease Product Name: Jotrol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 02, 2022
Details:
The U.S. patent covers the suspension of active ingredient resveratrol and other compounds in a micellar emulsion that can be delivered via oral capsule.
Lead Product(s): Resveratrol
Therapeutic Area: Neurology Product Name: Jotrol
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Lead Product(s): Resveratrol
Therapeutic Area: Neurology Product Name: Jotrol
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
